+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Whole Genome and Exome Sequencing Market: Focus on Product, Workflow, Application, End User, Country Data (16 Countries), and Competitive Landscape - Analysis and Forecast, 2019-2029

  • ID: 5055388
  • Report
  • May 2020
  • Region: Global
  • 222 Pages
  • BIS Research
1 of 5

Enquire about COVID-19 updates for this product.

Enquire Now
Global Whole Genome and Exome Sequencing Market to Reach $7,303.0 Million by 2029

FEATURED COMPANIES

  • Cancer Genetics, Inc.
  • Eurofins Scientific SE
  • F. Hoffmann-La Roche Ltd
  • General Electric Company
  • GENEWIZ, Inc.
  • Illumina, Inc.
  • MORE

Market Report Coverage - Whole Genome and Exome Sequencing

Market Segmentation

  • Product - Kits, Instruments
  • Workflow - Sample Extraction/Purification, Library Preparation, Library Quantification, Analysis (Bioinformatics)
  • Application - Oncology Sequencing, Microbial Sequencing, NIPT Sequencing, Rare Disease Sequencing, Translational Research Sequencing
  • End User - Research Centers, Academia and Government Institutes, Diagnostic Labs, Pharmaceutical and Biotechnology Companies

Regional Segmentation

  • North America - U.S., Canada, Mexico
  • Europe - Germany, France, Italy, U.K., Spain, Russia, Netherlands
  • Asia-Pacific - Japan, China, India, Australia, Singapore
  • Latin America - Brazil, Mexico
  • Rest-of-the-World - Kingdom of Saudi Arabia (K.S.A.), U.A.E., Palestine, Algeria

Growth Drivers

  • Rising Prevalence of Genetic Disorders
  • Increasing Prevalence of Various Types of Cancer, Globally
  • Increasing Research Funding in the Field of Genomics

Market Challenges

  • Expensive Sequencing Procedures and Their Applications in Medical Treatments
  • High Capital Requirement Hampering the Expansion of Global Reach
  • Stringent Regulatory Standards

Market Opportunities

  • Technological Advancements in Sample Preparation for Whole Genome and Exome Sequencing
  • Opportunity (by Product)
  • Opportunity (by Application)
  • Opportunity (by Region)

Key Companies Profiled

Agilent Technologies, Inc., Beijing Genomics Institute (BGI), Bio-Rad Laboratories, Inc. , Cancer Genetics, Inc., Eurofins Scientific SE, F. Hoffmann-La Roche Ltd, General Electric Company, GENEWIZ, Inc., Illumina, Inc., Laboratory Corporation of America Holdings, NoVo gene Corporation, Oxford Nanopore Technologies, Inc., Pacific Biosciences of California, Inc., QIAGEN N.V., Thermo Fisher Scientific Inc.

Key Questions Answered:

  •  What are the long-term and short-term impacts of whole genome and exome sequencing on the human health continuum?
  •  What are the major market drivers, challenges, and opportunities in the whole genome and exome sequencing?
  •  What are the key development strategies which are implemented by the major players in order to sustain in the competitive market?
  •  What are the key regulatory implications in the developed and developing regions for the global whole genome and exome sequencing market?
  •  How are service-based companies impacting the growth of the global whole genome and exome sequencing industry and further shaping up future trends?
  •  How each segment of the market is expected to grow during the forecast period from 2019 to 2029?
  •  Who are the leading players with significant offerings to the global whole genome and exome sequencing market? What is the expected market dominance for each of these leading players?
  •  Which companies are anticipated to be highly disruptive in the future, and why?
  •  What are challenges that are yet to be met by the global whole genome and exome sequencing market?

Market Overview

The whole genome and exome sequencing have grown significantly since the technology was first commercialized, but it is important to quantify that growth and describe future trends. The whole genome and exome industry is proliferating and the growth is expected to continue at its torrid pace. However, there are significant challenges that may dampen future growth if not addressed.

Our healthcare experts have found the whole genome and exome sequencing to be one of the most rapidly evolving technologies, and the global market for the whole genome and exome is predicted to grow at a CAGR of 26.94% over the forecast period of 2019-2029.

The combination of unmet clinical needs for better tools to predict, diagnose, treat, and monitor disease are significant factors driving the growth of the sequencing industry. Other factors driving growth include the increased understanding of the molecular basis of disease, patient demand, industry investment, and regulations that allow marketing of tests without FDA approval.

Despite rapid advanced sequencing industry growth, there are several key issues that will need to be addressed to facilitate future growth. The still relatively high total costs of delivering sequencing test results compared with other technology platforms, and limited coverage by payers, are the key challenges to the growth of this industry. Whole genome and exome sequencing remain relatively costly requiring initial equipment investment, specialized workforce requirements, and time-intensive variant interpretation.

Within the research report, the market is segmented on the basis of product, workflow, application, end users, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

Competitive Landscape

The exponential rise in the application of next generation sequencing on the global level has created a buzz among companies to invest in the products and services of whole genome and exome sequencing. Due to the diverse product portfolio and intense market penetration, whole genome and exome has been a pioneer in this field and been a significant competitor in this market.

On the basis of region, North America holds the largest share, due to improved healthcare infrastructure, rise in per capita income, and improvized reimbursement policies in the region. Apart from this, Latin America and the Asia-Pacific region are anticipated to grow at the fastest CAGR during the forecast period.

Enterprise License customers will receive an Excel spreadsheet containing additional data.

Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Cancer Genetics, Inc.
  • Eurofins Scientific SE
  • F. Hoffmann-La Roche Ltd
  • General Electric Company
  • GENEWIZ, Inc.
  • Illumina, Inc.
  • MORE

Executive Summary

1 Product Definition
1.1 Whole Genome Sequencing
1.2 Whole Exome Sequencing
1.3 Inclusion and Exclusion

2 Research Scope
2.1 Scope of the Study
2.2 Key Questions Answered in the Report

3 Research Methodology
3.1 Primary Data Sources
3.2 Secondary Data Sources
3.3 Market Estimation Model
3.4 Criteria for Company Profiling

4  Industry Insights
4.1 Overview
4.2 Legal Requirements and Framework in the U.S.
4.3 Legal Requirements and Framework in Europe
4.4 Legal Requirements and Framework in Asia-Pacific
4.4.1 Japan

5 Competitive Landscape
5.1 Mergers and Acquisitions
5.2 Product Launches and Product Updates
5.3 Synergistic Activities
5.4 Business Expansion Activities and Others
5.5 Market Share Analysis
5.6 Growth Share Analysis

6 Market Dynamics
6.1 Overview
6.2 Impact Analysis
6.3 Market Drivers
6.3.1 Rising Prevalence of Genetic Disorders
6.3.2 Increasing Prevalence of Various Types of Cancer, Globally
6.3.3 Increasing Research Funding in the Field of Genomics
6.4 Market Restraints
6.4.1 Expensive Sequencing Procedures and Their Applications in Medical Treatments
6.4.2 High Capital Requirement Hampering the Expansion of Global Reach
6.4.3 Stringent Regulatory Standards
6.5 Market Opportunities
6.5.1 Technological Advancements in Sample Preparation for Whole Genome and Exome Sequencing
6.5.2 Opportunity (by Product)
6.5.2.1 Kits
6.5.3 Opportunity (by Application)
6.5.3.1 DNA Sequencing
6.5.3.2 Metagenomics

7 Global Whole Genome and Exome Sequencing Market Overview
7.1 Introduction
7.2 Market Availability for Whole Genome and Exome Sequencing Market
7.3 Whole Genome and Exome Sequencing Market Technology Trends

8 Global Whole Genome and Exome Sequencing Market (by Product)
8.1 Overview
8.2 Kits
8.2.1 Library Preparation Kits
8.2.2 Target Enrichment Kits
8.3 Instruments

9 Global Whole Genome and Exome Sequencing Market (by Workflow)
9.1 Whole Genome Sequencing (WGS): By Workflow
9.1.1 WGS: Sample Extraction/Isolation/Purification
9.1.2 WGS: Library Preparation
9.1.3 WGS: Library Quantification
9.1.4 Analysis (Bioinformatics)
9.1.4.1 Services
9.1.4.2 Platforms
9.2 Whole Exome Sequencing: By Workflow
9.2.1 WES: Sample Extraction/Isolation/Purification
9.2.1.1 Targeted Sequencing
9.2.1.2 Amplicon-Based Sequencing
9.2.1.3 Capture-Based Sequencing
9.2.2 WES: Library Preparation
9.2.3 WES: Library Quantification
9.2.4 Analysis (Bioinformatics)
9.2.4.1 Services
9.2.4.2 Platforms

10 Global Whole Genome and Exome Sequencing Market (by Application)
10.1 Overview
10.2 Whole Genome Sequencing (WGS)
10.2.1 Oncology Sequencing
10.2.2 Microbial Sequencing
10.2.3 NIPT Sequencing
10.3 Whole Exome Sequencing (WES)
10.3.1 Oncology Sequencing
10.3.2 Rare Diseases Sequencing
10.3.3 Translational Research Sequencing

11 Global Whole Genome and Exome Sequencing Market (by End User)
11.1 Overview
11.2 Research Centres, Academia and Government Institutes
11.3 Diagnostic Labs
11.4 Pharmaceutical and Biotechnology Companies
11.5 Hospitals and Clinics
11.6 Other End Users

12 Global Whole Genome and Exome Sequencing Market (by Region)
12.1 Overview
12.2 North America
12.2.1 U.S.
12.2.2 Canada
12.3 Europe
12.3.1 Germany
12.3.2 France
12.3.3 U.K.
12.3.4 Italy
12.3.5 Spain
12.3.6 Netherlands
12.3.7 Russia
12.3.8 Rest-of-Europe
12.4 Asia-Pacific
12.4.1 China
12.4.2 Japan
12.4.3 Australia
12.4.4 India
12.4.5 Singapore
12.4.6 Rest-of-APAC
12.5 Latin America
12.5.1 Brazil
12.5.2 Mexico
12.5.3 Rest-of-Latin America
12.6 Rest-of-the-World

13 Company Profiles
13.1 Overview
13.2 Agilent Technologies, Inc.
13.2.1 Company Overview
13.2.2 Role of Agilent Technologies, Inc. in the Global Whole Genome and Exome Sequencing Market
13.2.3 Financials
13.2.4 Key Insights about Financial Health of the Company
13.2.5 SWOT Analysis
13.3 Beijing Genomics Institute (BGI)
13.3.1 Company Overview
13.3.2 Role of BGI in the Global Whole Genome and Exome Sequencing Market
13.3.3 SWOT Analysis
13.4 Bio-Rad Laboratories, Inc.
13.4.1 Company Overview
13.4.2 Role of Bio-Rad Laboratories, Inc. in the Global Whole Genome and Exome Sequencing Market
13.4.3 Financials
13.4.3.1 Key Insights about Financial Health of the Company
13.4.4 SWOT Analysis
13.5 Cancer Genetics, Inc.
13.5.1 Company Overview
13.5.2 Role of Cancer Genetics, Inc. in the Global Whole Genome and Exome Sequencing Market
13.5.3 Financials
13.5.4 Key Insights about Financial Health of the Company
13.5.5 SWOT Analysis
13.6 Eurofins Scientific SE
13.6.1 Company Overview
13.6.2 Role of Eurofins Scientific SE in the Global Whole Genome and Exome Sequencing Market
13.6.3 Financials
13.6.4 SWOT Analysis
13.7 F. Hoffmann-La Roche Ltd
13.7.1 Company Overview
13.7.2 Role of F. Hoffmann-La Roche Ltd in the Global Genome and Exome Sequencing Market
13.7.3 Financials
13.7.4 Key Insights About Financial Health of the Company
13.7.5 SWOT Analysis
13.8 General Electric Company
13.8.1 Company Overview
13.8.2 Role of General Electric Company in the Global Genome and Exome Sequencing Market
13.8.3 Financials
13.8.4 Key Insights about Financial Health of the Company
13.8.5 SWOT Analysis
13.9 GENEWIZ, Inc.
13.9.1 Company Overview
13.9.2 Role of GENEWIZ, Inc. in the Global Whole Genome and Exome Sequencing Market
13.9.3 SWOT Analysis
13.10 Illumina, Inc.
13.10.1 Company Overview
13.10.2 Role of Illumina, Inc. in the Global Whole Genome and Exome Sequencing Market
13.10.3 Financials
13.10.4 Key Insights about Financial Health of the Company
13.10.5 SWOT Analysis
13.11 Laboratory Corporation of America Holdings
13.11.1 Company Overview
13.11.2 Role of Laboratory Corporation of America Holdings in the Global Whole Genome and Exome Sequencing Market
13.11.3 Financials
13.11.4 SWOT Analysis
13.12 Novogene Corporation
13.12.1 Company Overview
13.12.2 Role of Novogene Corporation in the Global Whole Genome and Exome Sequencing Market
13.12.3 SWOT Analysis
13.13 Oxford Nanopore Technologies, Inc.
13.13.1 Company Overview
13.13.2 Role of Oxford Nanopore Technologies, Inc. in the Global Whole Genome and Exome Sequencing Market
13.13.3 SWOT Analysis
13.14 Pacific Biosciences of California, Inc.
13.14.1 Company Overview
13.14.2 Role of Pacific Biosciences of California, Inc. in the Global Whole Genome and Exome Sequencing Market
13.14.3 Financials
13.14.4 Key Insights About Financial Health of the Company
13.14.5 SWOT Analysis
13.15 QIAGEN N.V.
13.15.1 Company Overview
13.15.2 Role of QIAGEN N.V. in the Global Whole Genome and Exome Sequencing Market
13.15.3 Financials
13.15.4 Key Insights about Financial Health of the Company
13.15.5 SWOT Analysis
13.16 Thermo Fisher Scientific Inc.
13.16.1 Company Overview
13.16.2 Role of Thermo Fisher Scientific Inc. in the Global Whole Genome and Exome Sequencing Market
13.16.3 Financials
13.16.4 Key Insights about Financial Health of the Company
13.16.5 SWOT Analysis

14 Appendix
14.1 Related Reports

List of Tables
Table 1: Per Sample Clinical Cost of WGS and WES
Table 6.1: Impact Analysis
Table 8.1: Key Products and Application in Whole Genome and Exome Sequencing Market

List of Figures
Figure 1: Impact of Market Drivers and Market Restraints on the Global Whole Genome and Exome Sequencing Market
Figure 2: Global Whole Genome and Exome Sequencing Market (by Product), 2018 vs. 2029 ($Million)
Figure 3: Global Whole Genome and Exome Sequencing Market (by End User), 2018 vs. 2029 ($Million)
Figure 4: Global Whole Genome and Exome Sequencing Market Snapshot, 2018 and 2029 ($Million)
Figure 2.1: Global Whole Genome and Exome Sequencing Market Segmentation
Figure 3.1: Global Whole Genome and Exome Sequencing Market Methodology
Figure 3.2: Primary Research Methodology
Figure 3.3: Bottom-Up Approach (Segment-Wise Analysis)
Figure 4.1: Regulatory Scenario in Europe (by Country)
Figure 4.2: Assessment of Commercialization Strategy in Japan
Figure 5.1: Share of Key Developments and Strategies, January 2017–February 2020
Figure 5.2: Number of Product Launches (by Company), January 2016–December 2019
Figure 5.3: Synergistic Activities Share (by Company), January 2017–February 2020
Figure 5.4: Business Expansion Activities Share (by Company), January 2017–February 2020
Figure 5.5: Market Share Analysis for the Global Whole Genome and Exome Sequencing Market, 2018
Figure 5.6: Growth Share Matrix for Global Whole Genome and Exome Sequencing Market (by Company), 2017-2018
Figure 6.1: People Suffering from CF (Cystic Fibrosis), 2002-2017:
Figure 6.2: Number of Deaths (in Millions) by Different Forms of Cancer, 2018
Figure 6.3: Global Whole Genome and Exome Sequencing Market (Kits), 2019 and 2029
Figure 6.4: Global Whole Genome and Exome Sequencing Market (by Application:), 2019 and 2029
Figure 8.1: Global Whole Genome and Exome Sequencing Market (by Product)
Figure 8.2: Global Whole Genome and Exome Sequencing Market (Kits), 2018-2029
Figure 8.3: Global Whole Genome and Exome Sequencing Market (Library Preparation Kits), 2018-2029
Figure 8.4: Global Whole Genome and Exome Sequencing Market (Target Enrichment Kits), 2018-2029
Figure 8.5: Global Whole Genome and Exome Sequencing Market (Instruments),  2018-2029
Figure 9.1: Global Whole Genome and Exome Sequencing Market (WGS: Sample Extraction/Isolation/Purification), 2018-2029
Figure 9.2: Global Whole Genome and Exome Sequencing Market (WGS: Library Preparation), 2018-2029
Figure 9.3: Global Whole Genome and Exome Sequencing Market (by WGS: Library Quantification), 2018-2029
Figure 9.4: Global Whole Genome and Exome Sequencing Market (by Analysis), 2018-2029
Figure 9.5: Global Whole Genome and Exome Sequencing Market (by WGS: Analysis: Services), 2018-2029
Figure 9.6: Global Whole Genome and Exome Sequencing Market (WGS: Analysis: Platforms), 2018-2029
Figure 9.7: Global Whole Genome and Exome Sequencing Market (by WES: Sample Extraction/Isolation/Purification), 2018-2029
Figure 9.8: Global Whole Genome and Exome Sequencing Market (by WES: Sample Extraction: Targeted Sequencing), 2018-2029
Figure 9.9: Global Whole Genome and Exome Sequencing Market (WES: Sample Extraction: Amplicon Based Sequencing), 2018-2029
Figure 9.10: Global Whole Genome and Exome Sequencing Market (WES: Sample Extraction: Capture Based Sequencing), 2018-2029
Figure 9.11: Global Whole Genome and Exome Sequencing Market (WGS: Library Preparation), 2018-2029
Figure 9.12: Global Whole Genome and Exome Sequencing Market (WES: Library Quantification), 2018-2029
Figure 9.13: Global Whole Genome and Exome Sequencing Market (WES: Analysis: Services), 2018-2029
Figure 9.14: Global Whole Genome and Exome Sequencing Market (WES: Analysis: Paid Sources), 2018-2029
Figure 10.1: Global Whole Genome and Exome Sequencing Market (by Application)
Figure 10.2: Global Whole Genome and Exome Sequencing Market (Oncology Sequencing),2018-2029
Figure 10.3: Global Whole Genome and Exome Sequencing Market (Microbial Sequencing),2018-2029
Figure 10.4: Global Whole and Exome Sequencing Market (NIPT),2018-2029
Figure 10.5: Global Whole Genome and Exome Sequencing Market (Oncology Sequencing),2018-2029
Figure 10.6: Global Whole Genome and Exome Sequencing Market (Rare Diseases Sequencing),2018-2029
Figure 10.7: Global Whole Genome and Exome Sequencing Market (Translational Research Sequencing),2018-2029
Figure 11.1: Global Whole Genome and Exome Sequencing Market (by End User)
Figure 11.2: Global Market (Research Centres, Academia, and Government Institutes), 2018-2029
Figure 11.3: Global Whole Genome and Exome Sequencing Market (Diagnostic Labs), 2018-2029
Figure 11.4: Global Whole Genome and Exome Sequencing Market (Pharmaceutical and Biotechnology Companies), 2018-2029
Figure 11.5: Global Whole Genome and Exome Sequencing Market (Hospitals and Clinics), 2018-2029
Figure 11.6: Global Whole Genome and Exome Sequencing Market (Other End Users), 2018-2029
Figure 12.1: Global Whole Genome and Exome Sequencing Market (by Region), 2018 and 2029
Figure 12.2: Global Whole Genome and Exome Sequencing Market (by Region), 2018-2029
Figure 12.3: Global Whole Genome and Exome Sequencing Market Share (by Region), 2018
Figure 12.4: Global Whole Genome and Exome Sequencing Market Share (by Region), 2029
Figure 12.5: North America Whole Genome and Exome Sequencing Market, 2018-2029
Figure 12.6: North America: Market Dynamics
Figure 12.7: North America Whole Genome and Exome Sequencing Market (by Country), 2018-2029
Figure 12.8: U.S. Whole Genome and Exome Sequencing Market, 2018-2029
Figure 12.9: Canada Whole Genome and Exome Sequencing Market, 2018-2029
Figure 12.10: Europe Whole Genome and Exome Sequencing Market, 2018-2029
Figure 12.11: Europe: Market Dynamics
Figure 12.12: Europe Whole Genome and Exome Sequencing Market (by Country),  2018-2029
Figure 12.13: Germany Whole Genome and Exome Sequencing Market, 2018-2029
Figure 12.14: France Whole Genome and Exome Sequencing Market, 2018-2029
Figure 12.15: U.K. Whole Genome and Exome Sequencing Market, 2018-2029
Figure 12.16: Italy Whole Genome and Exome Sequencing Market, 2018-2029
Figure 12.17: Spain Whole Genome and Exome Sequencing Market, 2018-2029
Figure 12.18: Netherlands Whole Genome and Exome Sequencing Market, 2018-2029
Figure 12.19: Russia Whole Genome and Exome Sequencing Market, 2018-2029
Figure 12.20: Rest-of-Europe Whole Genome and Exome Sequencing Market, 2018-2029
Figure 12.21: Asia-Pacific Whole Genome and Exome Sequencing Market, 2018-2029
Figure 12.22: APAC: Market Dynamics
Figure 12.23: APAC Whole Genome and Exome Sequencing Market (by Country),  2018-2029
Figure 12.24: China Whole Genome and Exome Sequencing Market, 2018-2029
Figure 12.25: Japan Whole Genome and Exome Sequencing Market, 2018-2029
Figure 12.26: Australia Whole Genome and Exome Sequencing Market, 2018-2029
Figure 12.27: India Whole Genome and Exome Sequencing Market, 2018-2029
Figure 12.29: Singapore Whole Genome and Exome Sequencing Market, 2018-2029
Figure 12.30: RoAPAC Whole Genome and Exome Sequencing Market, 2018-2029
Figure 12.31: Latin America Whole Genome and Exome Sequencing Market, 2018-2029
Figure 12.32: Latin America: Market Dynamics
Figure 12.33: Latin America Whole Genome and Exome Sequencing Market (by Country), 2018-2029
Figure 12.34: Brazil Whole Genome and Exome Sequencing Market, 2018-2029
Figure 12.35: Mexico Whole Genome and Exome Sequencing Market, 2018-2029
Figure 12.36: Rest-of-Latin America Whole Genome and Exome Sequencing Market,  2018-2029
Figure 12.37: RoW Whole Genome and Exome Sequencing Market, 2018-2029
Figure 13.1: Total Number of Companies Profiled
Figure 13.2: Agilent Technologies, Inc.: Product Portfolio
Figure 13.3: Agilent Technologies, Inc.: Overall Financials, 2016-2018
Figure 13.4: Agilent Technologies, Inc.: Revenue (by Segment), 2016-2018
Figure 13.5: Agilent Technologies, Inc.: Revenue (by Region), 2016-2018
Figure 13.6: Agilent Technologies, Inc.: R&D Expenditure, 2016-2018
Figure 13.7: Agilent Technologies, Inc.: SWOT Analysis
Figure 13.8: BGI:Product Portfolio
Figure 13.9: BGI: SWOT Analysis
Figure 13.10: Bio-Rad Laboratories, Inc.: Product Offerings
Figure 13.11: Bio-Rad Laboratories, Inc.: Overall Financials, 2016-2018
Figure 13.12: Bio-Rad Laboratories, Inc.: Revenue (by Segment), 2016-2018
Figure 13.13: Bio-Rad Laboratories, Inc.: Revenue (by Region), 2016-2018
Figure 13.14: Bio-Rad Laboratories, Inc.: R&D Expenditure, 2016-2018
Figure 13.15: Bio-Rad Laboratories, Inc.: SWOT Analysis
Figure 13.16: Cancer Genetics, Inc.; Product Portfolio:
Figure 13.17: Cancer Genetics, Inc.: Overall Financials, 2016-2018
Figure 13.18: Cancer Genetics, Inc.: Revenue (by Segment), 2016-2018
Figure 13.19: Cancer Genetics, Inc.: R&D Expenditure, 2016-2018
Figure 13.20: Cancer Genetics, Inc.: SWOT Analysis
Figure 13.21: Eurofins Scientific SE: Overall Financials, 2016-2018
Figure 13.22: Eurofins Scientific SE: Revenue (by Region), 2016-2018
Figure 13.23: Eurofins Scientific SE.: SWOT Analysis
Figure 13.24: F. Hoffmann-La Roche Ltd: Product Portfolio
Figure 13.25: F. Hoffmann-La Roche Ltd: Overall Financials, 2017-2019
Figure 13.26: F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2017-2019
Figure 13.27: F. Hoffmann-La Roche Ltd: Revenue (by Region), 2017-2019
Figure 13.28: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2017-2019
Figure 13.29: F. Hoffmann-La Roche Ltd: SWOT Analysis
Figure 13.30: GE Healthcare: Product Portfolio
Figure 13.31: General Electric Company: Overall Financials, 2016-2018
Figure 13.32: General Electric Company: Revenue (by Segment), 2016-2018
Figure 13.33: General Electric Company: Revenue Split for Healthcare, 2016-2018
Figure 13.34: General Electric: Healthcare Revenue (by Region), 2016-2018
Figure 13.35: General Electric Company: R&D Expenditure, 2016-2018
Figure 13.36: General Electric Company: SWOT Analysis
Figure 13.37: GENEWIZ, Inc.: Overall Service Portfolio
Figure 13.38: GENEWIZ, Inc.: SWOT Analysis
Figure 13.39: Illumina, Inc.: Overall Product Portfolio
Figure 13.40: Illumina, Inc.: Overall Financials, 2016-2018
Figure 13.41: Illumina, Inc.: Revenue (by Segment), 2016-2018
Figure 13.42: Illumina, Inc.: Revenue (by Region), 2016-2018
Figure 13.43: Illumina, Inc.: R&D Expenditure, 2016-2018
Figure 13.44: Illumina, Inc.: SWOT Analysis
Figure 13.45: Laboratory Corporation of America Holdings: Overall Product Portfolio
Figure 13.46: Laboratory Corporation of America Holdings: Overall Financials, 2016-2018
Figure 13.47: Laboratory Corporation of America Holdings: Revenue (by Segment),  2016-2018
Figure 13.48: Laboratory Corporation of America Holdings: Revenue (by Region), 2018
Figure 13.49: Laboratory Corporation of America Holdings: SWOT Analysis
Figure 13.53: Pacific Biosciences of California, Inc.: Overall Product Portfolio
Figure 13.54: Pacific Biosciences of California, Inc.: Overall Financials, 2016-2018
Figure 13.56: Pacific Biosciences of California, Inc.: Revenue (by Region), 2016-2018
Figure 13.57: Pacific Biosciences of California, Inc.: R&D Expenditure, 2016-2018
Figure 13.58: Pacific Biosciences of California, Inc.: SWOT Analysis
Figure 13.59: QIAGEN N.V.: Product Portfolio
Figure 13.60: QIAGEN N.V.: Overall Financials, 2016-2018
Figure 13.61: QIAGEN N.V.: Revenue (by Segment), 2016-2018
Figure 13.62: QIAGEN N.V.: Revenue (by Region), 2016-2018
Figure 13.63: QIAGEN N.V.: R&D Expenditure, 2016-2018
Figure 13.64: QIAGEN N.V.: SWOT Analysis
Figure 13.65: Thermo Fisher Scientific Inc.: Product Portfolio
Figure 13.66: Thermo Fisher Scientific Inc.: Overall Financials, 2016-2018
Figure 13.67: Thermo Fisher Scientific Inc.: Revenue (by Segment), 2016-2018
Figure 13.68: Thermo Fisher Scientific Inc.: Revenue (by Region), 2016-2018
Figure 13.69: Thermo Fisher Scientific Inc.: R&D Expenditure, 2016-2018
Figure 13.70: Thermo Fisher Scientific Inc.: SWOT Analysis

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Cancer Genetics, Inc.
  • Eurofins Scientific SE
  • F. Hoffmann-La Roche Ltd
  • General Electric Company
  • GENEWIZ, Inc.
  • Illumina, Inc.
  • MORE

According to a new market intelligence report titled “Global Whole Genome and Exome Sequencing Market - Analysis and Forecast, 2019-2029”, the global whole genome and exome sequencing market was valued at $497.1 million in 2018 and is anticipated to grow over $7,303.0 million by 2029. The global whole genome and exome sequencing market are expected to grow at double-digit compound annual growth rate in the forecast period 2019-2029, aided primarily by the impressive growth in the underlying services market.

Whole genome sequencing is a one of the comprehensive methods for analyzing entire genomes. Genomic information has been instrumental in identifying inherited disorders, characterizing the mutations that drive cancer progression, and tracking disease outbreaks. Further, whole exome sequencing is the technique for sequencing all the exome and protein-coding genes in genome. This technique includes selection of the subset of the DNA that encodes proteins or exons which is followed by sequencing of the exome DNA using high throughput DNA sequencing methods.

According to Nitish Kumar, Analyst, “North America is the leading contributor in the global whole genome and exome sequencing market and contributed approximately 41.87% to the global market value in 2018. This region is anticipated to grow at a CAGR of 24.76% during the forecast period 2019-2029 and continue dominating the global market in 2029. However, the Asia-Pacific region is expected to grow at an impressive CAGR of 30.38% during the forecast period from 2019-2029. The European region also contributed a significant share of 27.83% to the global market in 2018 and is anticipated to grow at a CAGR of 26.21% during the forecast period 2019-2029.”

Research Highlights:

Oncology Sequencing as an application is expected to witness a robust CAGR of 28.88% during the forecast period 2019-2029. However, whole genome and exome sequencing market for microbial sequencing as an application area are anticipated to witness the growth of 29.39% during the forecast period 2019-2029.

F. Hoffmann-La Roche Ltd is currently the largest shareholder in the global companion diagnostics market. Its market dominance is attributed to the company’s presence within the market through its manufacturing, and services, led by dedicated products.

This market intelligence report provides a multi-dimensional view of the global whole genome and exome sequencing market in terms of market size and growth potential. This research report aims at answering various aspects of the global whole genome and exome sequencing market with the help of key factors driving the market, restraints that can possibly inhibit the overall growth of the market, and the current growth opportunities that are going to shape the future trajectory of the market expansion.

Furthermore, the competitive landscape chapter in the report explicates the competitive nature of the global market and enables the reader to get acquainted with the recent market activities, such as product launches and approvals, partnerships, collaborations, business expansions, as well as mergers and acquisitions.  The research report provides a comprehensive analysis of the product sales, manufacturers, service providers, and trend analysis by segment, and growth share analysis by region. Additionally, the report provides a comprehensive analysis and an opportunity analysis for the entire whole genome and exome sequencing market for 2018 to 2029.

This report is a meticulous compilation of research on more than 80 players in the market ecosystem and draws upon insights from in-depth interviews with the key opinion leaders of more than 20 leading and emerging companies, market participants, and vendors. The report also comprises 15 detailed company profiles including several key players such as Agilent Technologies, Inc., Beijing Genomics Institute (BGI), Bio-Rad Laboratories, Inc., Cancer Genetics, Inc., Eurofins Scientific SE, F. Hoffmann-La Roche Ltd, General Electric Company, GENEWIZ, Inc., Illumina, Inc., Laboratory Corporation of America Holdings, NoVo gene Corporation, Oxford Nanopore Technologies, Inc., Pacific Biosciences of California, Inc., QIAGEN N.V., Thermo Fisher Scientific Inc.

The answers to the following key questions can be derived from this report:

  • What are the long-term and short-term impacts of whole genome and exome sequencing on the human health continuum?
  • What are the major market drivers, challenges, and opportunities in the whole genome and exome sequencing?
  • What are the key development strategies which are implemented by the major players in order to sustain in the competitive market?
  • What are the key regulatory implications in the developed and developing regions for the global whole genome and exome sequencing market?
  • How are service-based companies impacting the growth of the global whole genome and exome sequencing industry and further shaping up future trends?
  • How each segment of the market is expected to grow during the forecast period from 2019 to 2029?
  • Who are the leading players with significant offerings to the global whole genome and exome sequencing market? What is the expected market dominance for each of these leading players?
  • Which companies are anticipated to be highly disruptive in the future, and why?
  • What are challenges that are yet to be met by the global whole genome and exome sequencing market?
Note: Product cover images may vary from those shown
5 of 5
  • Agilent Technologies, Inc.
  • Beijing Genomics Institute (BGI)
  • Bio-Rad Laboratories, Inc.
  • Cancer Genetics, Inc.
  • Eurofins Scientific SE
  • F. Hoffmann-La Roche Ltd
  • GENEWIZ, Inc.
  • General Electric Company
  • Illumina, Inc.
  • Laboratory Corporation of America Holdings
  • Novogene Corporation
  • Oxford Nanopore Technologies, Inc.
  • Pacific Biosciences of California, Inc.
  • QIAGEN N.V.
  • Thermo Fisher Scientific Inc.
Note: Product cover images may vary from those shown
Adroll
adroll